The
Discovery Labs

The Discovery Labs is a Global Platform Company building large scale enterprise-level life sciences and technology companies and campuses designed to facilitate the expedition of cell and gene therapies from bench to bedside.

The Center for Breakthrough Medicines

The Center for Breakthrough Medicines is the world's largest and most advanced single solution cell and gene therapy contract development and manufacturing organization (CDMO).

The 
Discovery 
Labs

The Discovery Labs is a Global Platform Company building large scale enterprise-level life sciences and technology companies and campuses designed to facilitate the expedition of cell and gene therapies from bench to bedside.

The Center for Breakthrough Medicines

The Center for Breakthrough Medicines is the world's largest and most advanced single solution cell and gene therapy contract development and manufacturing organization (CDMO).

Come Discover With Us

THE COLONY

The Discovery Labs is establishing THE COLONY which will provide custom built discovery labs, breakthrough funding, sponsored research agreements, housing and relocation for the world’s leading iconic experts in cell and gene therapy.

THE COLONY will seek to work hand in hand with scientists from both academic and pharmaceutical institutions to unlock and expedite groundbreaking therapies.

The ability for the industry’s greatest scientists to cohabitate, collaborate, cooperate, and communicate via technology and in person will create an exponential therapeutic “X FACTOR.” THE COLONY seeks to unlock institutional barriers prohibiting the world’s greatest scientists from moving at a pace necessary in today’s ever-changing therapeutic revolution. THE COLONY will partner with the institutions where the scientists currently work by providing equity, license fees, and revenue sharing.

Affiliates of The 
Discovery 
Labs

Discover Here

We have reimagined the workspace, delivering collaborative, innovative, coworking environments for Healthcare, Life Science, and Tech-Enabled companies.
We provide unparalleled infrastructure to allow companies to utilize their capital and enrich their businesses.

Discover Here

We have reimagined the workspace, delivering collaborative, innovative, coworking environments for Healthcare, Life Science, and Tech-Enabled companies.
We provide unparalleled infrastructure to allow companies to utilize their capital and enrich their businesses.

The Discovery Labs King of Prussia

Located in the heart of the Cellicon Valley, where cell and gene therapy was invented. 1.6 million square feet of CDMO, research and development, administrative offices, dining, daycare, and fitness amenities. Our 640,000 Square foot Phase 1 campus, The Innovation Renaissance, provides build-out and collaboration opportunities and is currently occupied by the finest life science organizations in the world. Our Phase 2 facility, Innovation 411, is connected by internal floor to ceiling glass corridors and separated by indoor and outdoor atriums providing world-class, employee-centric, inspirational, collaborative space needed to recruit and retain the finest talent. Innovation 411 is capable of adding up to 4 million square feet of expansion space to accommodate every growing need of our clients ON LOCATION. Our entire facility is supported by an extensive array of infrastructure, which provides 100% backed-up systems and is IN PLACE TODAY ready to be customized for your specific needs.

Phase 1: Innovation Renaissance

Innovation Renaissance, a 645,741 SF, World-Class, Transit-Oriented, Value-Add Life Sciences, Healthcare and Technology Park is located in King of Prussia, Pennsylvania. The Innovation Park is split up into 14 Office, Pharma-Quality FDA Lab, and Last-Mile Distribution buildings on 80 acres equipped with walking trails, fitness, a daycare and brew pub for all tenants. Innovation Renaissance is located in the prestigious triumvirate markets of Gulph Mills, Conshohocken and Radnor, PA. Due to its coveted location and the explosion of the Cell and Gene Therapy industry, Innovation Renaissance has established itself as the premier Life Sciences and Healthcare campus in our region and competes directly with University City, locally, and Cambridge, Massachusetts, nationally, for major Life Sciences and Healthcare tenants.

Phase 2: Innovation 411

Innovation 411 is a one million square foot facility that offers office, cGMP cell and gene therapy lab, and manufacturing space for companies of all sizes. The site’s world-class infrastructure expands the Cellicon Valley footprint and provides unrivaled capacity, redundant power, and utilities to ensure continuous and reliable functionality of all tenant processes. The Discovery Labs sits on 200 acres of land for further property development to guarantee that companies never outgrow their space.
Location Aerial

Campus Aerial

Campus Plan

Infrastructure as a Service™

Our Infrastructure as a Service offering provides everything necessary for state-of-the-art businesses and life science companies to operate, including:

Business

  • 8 mega watts of backup power
  • 5 diesel generators with 1.6 MW each
  • Dual-grid Electrical Feed
  • Fiber Service Provided by Crown Castle, Verizon and Comcast
  • Utility Service provided by PECO gas and electric
  • Water Service Provided by Aqua PA
  • 360° orientation of the buildings distributes natural light into the entire campus

Life Sciences

  • 8 megawatts of backup power
  • 8 chiller plants
  • 4 steam plant boilers
  • 3 oil-free air compressor
  • Dual-grid Electrical Feed
  • Laboratory Gas + Other Systems
  • Additional World-Class Infrastructure

411 Swedeland Road, King of Prussia, PA

An Epicenter of Innovation

A prime location at the intersection of major train and bus routes, highways including Routes 76, 476, and 202.
With free parking, zero wage tax, and the ability to have lunch with your kids and head back to work, King of Prussia ensures exceptional employee productivity and satisfaction.

PRESS

The Discovery Labs Select Greater Philadelphia Podcast interview with CEO and Founder Brian O’Neill.

Board of Directors

Marco Chacón, PhD
Chairman of the Board – Marco Chacón, PhD

“Setting the bar for the CDMO model”

Dr. Chacón is the Founder and former Chairman of Paragon Bioservices, Inc., a CDMO that specialized in process development and GMP manufacturing of viral vectors for gene therapy. In April of 2019 Paragon Bioservices, Inc. entered into a definitive agreement of sale for $1.2 billion with Catalent. Chacón is the Founder & President of IRAZÚ Bio-Holdings LLC., a company dedicated developing indications that promote survival, prevent disease and improve quality of life for the elderly. The company is also developing technology in the fields of immuno-oncology and gene therapy. Formerly, Chacón served as Assistant Vice President of Industry Alliances at the University of Maryland, Baltimore. His educational background includes a Bachelor of Science degree from Youngstown State University and a Ph.D. in Nutritional Sciences from the University of Maryland. He currently serves on the Board of Trustees of the University of Maryland Foundation and was appointed in 2016 to the Life Sciences Advisory Board by Governor Lawrence J. Hogan, Jr. Additionally, Dr. Chacón is the founding chair of The Board of Visitors of the University of Maryland Graduate School.

Brian O’Neill
Board of Directors – Brian O’Neill

“Investing with a higher purpose”

Mr. O’Neill is the Founder, Chairman and CEO of MLP Ventures, a leading venture capital and real estate investment firm. MLP Ventures creates companies that utilize real estate as an integral part of their business, as well as internet-based marketplaces. Under his leadership, MLP Ventures has developed millions of square feet of laboratory, office, industrial, retail and residential real estate throughout the Northeast. All of MLP companies and real estate recycle existing buildings, which often require environmental remediation. Mr. O’Neill has a track record of starting, scaling and operating healthcare organizations.

Alex Karnal
Board of Directors – Alex Karnal

“Healthcare initiatives for underserved communities”

Mr. Karnal is a Partner and co-manager of all of Deerfield’s assets with Jim Flynn. He also serves as a member of Deerfield’s Trading and Private Transactions teams focused on the intersection of optimal security expression of an investment thesis while meeting the financial needs of partner companies. Alex is very active in The Deerfield Foundation, which supports healthcare initiatives for underserved communities and is funded by Deerfield’s profits and employees. He also served as Vice Chairman on the board of the Children’s Health Fund, a national pediatric mobile healthcare program delivering health services to disadvantaged children and their families. Additionally, Alex serves on the board of Recovery Centers of America where the team works relentlessly to deliver world-class community-based addiction treatment. Alex is a graduate of the Massachusetts Institute of Technology where he studied finance and economics and is currently completing his Master’s in biotechnology at Johns Hopkins.

Jack Stoddard
Board of Directors – Jack Stoddard

“Make primary care easier to access, insurance benefits simpler to understand and use and prescription drugs more affordable”

Mr. Stoddard most recently served as COO of Haven the healthcare collaboration from J.P. Morgan, Amazon and Berkshire Hathaway. Prior to this he served as an executive general manager for digital health at Comcast. Previously, he was on the founding team of Accolade, a Comcast Ventures-backed start-up that helps workers manage their health benefits. He was also part of the executive team that created claims processing engine Optum, which was later acquired by United Health. He is a senior operating leader with over two decades of experience applying technology, data, science, people, and design thinking to improve the healthcare consumer experience, elevate clinical quality and lower the total cost of care. He has proven leadership experience in understanding the market, setting growth strategy, and scaling transformational healthcare companies, including: Haven, Accolade, Optum, Health Dialog, and The Advisory Board. Jack holds an MBA from Harvard Business School and earned his bachelor’s degree at Denison University with highest honors. He serves on the boards of directors of Carrot, backed by Khosla Ventures and Eden Health, backed by Greycroft. He has also served on the Board of Trustees of the Philadelphia Outward Bound School.

Eustace Mita
Board of Directors – Eustace Mita

“Unwavering faith, always maintaining a positive attitude, how to be a leader, humility, and so much more.”

Mr. Mita is Chairman and Chief Executive Officer of Icona Resorts, which owns and manages hotel properties in Avalon, Diamond Beach and Cape May, New Jersey. Mr. Mita is also Chairman of Mita Management, a company with interests in automotive and real estate, and is the Chief Executive Officer of Achristavest, LLC, a developer of waterfront properties in New Jersey, Nantucket, Maryland, Utah and Pennsylvania. Prior to forming Mita Management and Achristavest, Mr. Mita was the President and Chief Executive Officer of HAC Group, one of the world’s largest auto dealer training and consulting groups, with operations in nineteen countries, including Europe and Asia. In 2000, under Mr. Mita’s leadership, HAC merged with Reynolds & Reynolds, which has approximately 5,000 employees and a network of 10,000 dealer customers worldwide.

Matthew McDevitt
Board of Directors – Matthew McDevitt

“As one of BioMed’s founders, Matt has been at the centre of our success in building a world-class tenant roster within every one of our seven core markets.”

Mr. McDevitt specializes in the leasing and sale of life-sciences real estate for tenants and landlords. Matthew founded and served as Executive Vice President of Real Estate for BioMed Realty Trust, Inc. where he played an instrumental role in all acquisitions and major lease transactions for the company. During his 10-year span, he maximized the shareholder value, growing its market capitalization from $475 million to $8 billion. Prior to BioMed, Matthew served as president of McDevitt Real Estate Services, Inc., a full-service real estate provider focusing on the life science industry. Before founding MRES, he spent 10 years as a commercial real estate broker in the Washington, D.C. Metropolitan area.

Tony Khoury
Board of Directors – Tony Khoury

“We raise awareness of many life-threatening diseases, but also bring our team and our client’s team closer to the actual patients that will be impacted by our work.”

Tony is a 15 year veteran and leader in the biotech and pharmaceutical industry. As a member of the Project Farma leadership committee, Tony has spearheaded Project Farma’s growth in the gene and cell therapy space including building gene therapy facilities for Avexis. Tony has extensive experience with small and large molecules including biologics, biosimilars, and gene and cell therapies. He has worked with small and large biotech companies including gene and cell therapy startups and CMOs/CROs. He has led global programs greater than $350+ million in the following disciplines: project management, turnkey facility builds, automation, validation, engineering and serialization track and trace.

Audrey Greenberg
Board of Directors – Audrey Greenberg

“There is a scarcity of manufacturing, which is complex, expensive, and highly regulated. With this additional manufacturing capacity, The Discovery Labs Center for Breakthrough Medicine will fulfill the promise of gene and cell therapies.”

Ms. Greenberg has over 30 years of experience in strategic business management, finance and accounting having served as Chief Financial Officer at CBRE Global Investors ($100 billion total AUM) and ING Clarion ($50 billion total AUM). In addition to overseeing accounting and reporting, investor relations, audit, tax, compliance, rating agency relations, information technology, human resources and new business development, she also executed billions of dollars in real estate acquisitions/dispositions and fund-level and property-level debt financings. Greenberg was also part of the capital raising team having raised over $100 million from the world’s largest institutional investors including sovereigns, pension funds and endowments. Greenberg has expertise in tax structures, REIT rules and compliance as well as off shore and feeder funds. Prior to her tenure as a CFO, Ms. Greenberg worked as an investment banker at Morgan Stanley and Merrill Lynch as well as a public accountant at Deloitte & Touche. Ms. Greenberg has an MBA from the Wharton School at the University of Pennsylvania and is a registered CPA in Illinois.

Now Hiring 2,000 New Team Members Through Nucleus

Contact Us Today

Contact Us

Joseph Corcoran

SVP, Corporate Development and Leasing

Audrey Greenberg

Executive Director
Menu

The World's Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.

Now Reserving Capacity